Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT8ZYBQ)

• DTT Name: Serine/threonine-protein kinase ATR (FRP1) DTT Info
• Gene Name: ATR

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD6738	DM0PFNC	Small-cell lung cancer	2C25.Y	Phase 2	[1]
Camonsertib	DMOPPXY	Aggressive cancer	2A00-2F9Z	Phase 1/2	[2]
RP-3500	DM9FNC8	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
BAY1895344	DML781M	Lymphoma	2A80-2A86	Phase 1	[4]
M1774	DMP8QY2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
M4344	DMQBO3V	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
VX-970	DMR9PCT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZ20	DMNQ3HV	Discovery agent	N.A.	Investigative	[7]
CGK733	DM8OAN9	Discovery agent	N.A.	Investigative	[8]
VE-821	DM0UXNF	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]

References

• [1] National Cancer Institute Drug Dictionary (drug id 754022).
• [2] Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411.
• [3] Clinical pipeline report, company report or official report of Repare Therapeutics.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] National Cancer Institute Drug Dictionary (drug name M1774).
• [6] ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
• [7] Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14;56(5):2125-38.
• [8] Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.